Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
|Product Development Manager, Disposable Medical Products||
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|
|Neurovascular Intervention Product Sales Rep, North East||
|Multiple Locations, SL_Multiple Locations|
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||